Advertisement
Advertisement
COLL
Collegium Pharmaceutical, Inc. Common Stock
28.23
USDSponsored
+0.08
+0.28%
Aug 14, 15:59 UTC -4
Closed
After-Market
28.25
+0.02
+0.09%
COLL Earnings Reports
Positive Surprise Ratio
COLL beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$228.80M
/$2.03
Implied change from Q2 26 (Revenue/ EPS)
+14.47%
/+5.73%
Implied change from Q3 25 (Revenue/ EPS)
+9.28%
/-9.78%
Collegium Pharmaceutical, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, COLL reported earnings of 1.92 USD per share (EPS) for Q2 26, beating the estimate of 1.74 USD, resulting in a 9.75% surprise. Revenue reached 199.88 million, compared to an expected 205.23 million, with a -2.61% difference. The market reacted with a -18.55% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of 2.03 USD, with revenue projected to reach 228.80 million USD, implying an increase of 5.73% EPS, and increase of 14.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Collegium Pharmaceutical, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Collegium Pharmaceutical, Inc. Common Stock reported EPS of $1.92, beating estimates by 9.75%, and revenue of $199.88M, -2.61% below expectations.
How did the market react to Collegium Pharmaceutical, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -18.55%, changed from $35.74 before the earnings release to $29.11 the day after.
When is Collegium Pharmaceutical, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Collegium Pharmaceutical, Inc. Common Stock's next earnings report?
Based on 5
analysts, Collegium Pharmaceutical, Inc. Common Stock is expected to report EPS of $2.03 and revenue of $228.80M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement